chufangao/CTO huggingface dataset:
Clinical trial NCT03094611: Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
Official title: Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: the study was closed early due to competing trials
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-30
Primary completion date: 2020-03-11
Completion date: 2020-03-11
Clinical trial NCT04049617: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
Official title: A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects With Advanced Solid Tumors
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Gilead decision to terminate
Enrollment: 18.0 (ACTUAL)
Number of arms: 9.0
Start date: 2019-08-26
Primary completion date: 2021-03-30
Completion date: 2021-03-30
Baseline population: Safety Analysis Set included data from all participants who received at least 1 dose of study treatment, with treatment assignments designated according to the actual treatment received.
Limitations and caveats: Due to early termination, the study did not proceed to dose expansion phase.
Plan to share individual participant data: NO
Clinical trial NCT04206761: Investigating the Effects of QVM149 on MRI Ventilation Defects
Official title: Xenon MRI Probing vEntilation Response to Triple Therapy (QVM149)
Acronym: XPERTT
Sponsor: Western University, Canada (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: issues related to Covid-19 restrictions/shutdowns
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-01
Primary completion date: 2022-07-01
Completion date: 2022-12-01
Plan to share individual participant data: NO
Clinical trial NCT02502006: Variability in Response to Non-steroidal Anti-inflammatory Drugs
Official title: A Double-blind, Placebo-controlled Investigation of Inter-individual Variability in Pharmacologic Response to Non-steroidal Anti-inflammatory Drugs
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Funding was not available to complete enrollment
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-11-30
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Clinical trial NCT05050006: ITIL-168 in Advanced Melanoma
Official title: A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Acronym: DELTA-1
Sponsor: Instil Bio (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business Decision
Enrollment: 29.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-10-07
Primary completion date: 2023-02-27
Completion date: 2023-02-27
Plan to share individual participant data: NO
Clinical trial NCT03858166: Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
Official title: The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies
Sponsor: Shandong University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Sponsor Termination
Enrollment: 68.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-01
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT04009460: A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
Official title: An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES101 in Patients With Advanced Solid Tumors
Sponsor: Elpiscience Biopharma, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's clinical development strategy adjustment
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-28
Primary completion date: 2022-04-22
Completion date: 2022-04-22
Plan to share individual participant data: NO
Clinical trial NCT01951885: Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Official title: Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 101.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-07
Primary completion date: 2020-10-09
Completion date: 2021-08-11
Baseline population: All participants that went on study
Clinical trial NCT04561375: Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery
Official title: A Pilot Study Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery From Ambulatory Surgery
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: For practical reasons of slow enrollment
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-11
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Clinical trial NCT05176691: HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Official title: A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)
Sponsor: Hutchmed (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: HUTCHMED has decided to discontinue the HMPL 760 study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-02-15
Primary completion date: 2022-11-16
Completion date: 2022-11-16
Clinical trial NCT04153409: A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
Official title: A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
Sponsor: Lateral Pharma Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-24
Primary completion date: 2020-02-15
Completion date: 2020-04-10
Plan to share individual participant data: NO
Clinical trial NCT03296436: A Pilot Study to Assess the Efficacy of NEOX® CORD 1K® in the Treatment of Complex Diabetic Wounds
Official title: A Pilot Study to Assess the Efficacy of NEOX® CORD 1K® in the Treatment of Complex Diabetic Wounds
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor decision - sponsor will be initiating a phase 3 mid-2019
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-31
Primary completion date: 2021-01-31
Completion date: 2021-10-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04032158: Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
Official title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Sponsor: EMD Serono (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0073. Consequently, this trial terminated early.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-26
Primary completion date: 2020-04-16
Completion date: 2020-04-16
Limitations and caveats: Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0073. Consequently, this trial terminated early, therefore, it was decided as per Statistical Analysis Plan not to report the efficacy data for this study.
Plan to share individual participant data: YES
IPD sharing description: Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html
Clinical trial NCT05378945: Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Official title: A Phase 3, Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Chinese Population
Sponsor: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 340.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-22
Primary completion date: 2023-04-04
Completion date: 2023-04-04
Clinical trial NCT00659126: Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
Official title: A Phase II Study of Ferumoxytol and Gadolinium Magnetic Resonance Imaging at 3T and 7T in Subjects With Primary or Metastatic Brain Tumors Either Before or After Therapy
Sponsor: OHSU Knight Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Loss of funding
Enrollment: 40.0 (ACTUAL)
Number of arms: 1.0
Start date: 2006-11-16
Primary completion date: 2019-12-31
Completion date: 2020-12-31
Clinical trial NCT05351554: A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
Official title: A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis
Acronym: RESOLVE-Heart
Sponsor: Kinevant Sciences GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor business decision not related to safety
Enrollment: 1.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-08-23
Primary completion date: 2022-11-15
Completion date: 2022-12-13
Plan to share individual participant data: NO
Clinical trial NCT01881308: Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Official title: REmission in Rheumatoid Arthritis - Assessing WIthrawal of Disease-modifying Antirheumatic Drugs in a Non-inferiority Design
Acronym: ARCTIC REWIND
Sponsor: Diakonhjemmet Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 320.0 (ACTUAL)
Number of arms: 5.0
Start date: 2013-06-17
Primary completion date: 2020-01-31
Completion date: 2022-01-31
Plan to share individual participant data: YES
IPD sharing description: The authors commit to making the relevant anonymized patient level data available on reasonable request.
IPD time frame: Data will be available within 12 months of study completion.
IPD access criteria: Data access requests will be reviewed by the study steering committee, and requestors will be required to sign a data access agreement.
Clinical trial NCT02332928: Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy
Official title: Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy: A Double Blind Placebo-Controlled Trial
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-03-25
Primary completion date: 2021-06-02
Completion date: 2021-06-02
Limitations and caveats: The study had an initial goal of 142 patients, with interim analysis at half recruitment. Upon recommendation from the Data and Safety Monitoring Committee (DSMC), the study concluded at interim analysis due to lack of efficacy.
Clinical trial NCT04177693: Pharmacokinetics and Hepatic Safety of EGCG
Official title: Pharmacokinetics and Hepatic Safety of EGCG
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-24
Primary completion date: 2022-01-31
Completion date: 2022-01-31
Clinical trial NCT02601209: Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Official title: A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Interim monitoring
Enrollment: 151.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-11-30
Primary completion date: 2018-12-07
Completion date: 2022-07-11
Baseline population: Registered Phase I patients and Randomized Phase II patients
Clinical trial NCT05438251: Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B)
Official title: Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B)
Sponsor: Oneness Biotech Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study halted prematurely and will not resume.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-08-04
Primary completion date: 2024-04-03
Completion date: 2024-04-03
Plan to share individual participant data: NO
Clinical trial NCT03791398: BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC
Official title: BrUOG 379: A Phase Ib/II Single Arm Study of ONC201 Plus Nivolumab in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) Patients
Acronym: 379
Sponsor: Brown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 13.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-11-15
Primary completion date: 2021-06-16
Completion date: 2021-08-05
Baseline population: No patients were enrolled to dose level 2 or 3.
Plan to share individual participant data: NO
Clinical trial NCT02908490: Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?
Official title: Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow recruitment, lack of continued funding
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-01
Primary completion date: 2020-06-04
Completion date: 2020-12-31
Plan to share individual participant data: YES
Clinical trial NCT04210843: Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab
Official title: A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study was terminated due to a strategic decision by Novartis to discontinue development of ligelizumab in CSU. This decision was not based on any safety concerns.
Enrollment: 1033.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-08
Primary completion date: 2022-09-01
Completion date: 2022-09-01
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02689453: Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
Official title: A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-19
Primary completion date: 2021-06-15
Completion date: 2021-06-15
Plan to share individual participant data: YES
IPD sharing description: All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request.
IPD time frame: Clinical data available during the study and indefinitely.
IPD access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI).
Clinical trial NCT05008510: P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
Official title: Phase 2 Clinical Efficacy and Safety Study of Sabizabulin (VERU-111) Monotherapy and Sacituzumab Govitecan-hziy/Sabizabulin Combination Therapy for the Treatment of Metastatic Triple Negative Breast Cancer
Acronym: VERU-111
Sponsor: Veru Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Decided to halt and will potentially reopen in the future.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-30
Primary completion date: 2022-07-30
Completion date: 2023-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04317300: Feasibility of Treatment for Vaping Cessation
Official title: The Feasibility of Treatment for Vaping Cessation
Acronym: VAPEscape
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: medication has not been available for the intervention
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-02-01
Primary completion date: 2023-02-01
Completion date: 2023-02-01
Plan to share individual participant data: NO
Clinical trial NCT02749292: Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
Official title: Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare
Acronym: MAINTANCAVAS
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Due to the coronavirus disease 2019 (COVID-19) pandemic and the deleterious impact of rituximab on vaccination efficacy, the trial was concluded before reaching the target enrollment of 200.
Enrollment: 115.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2022-01-31
Completion date: 2022-01-31
Limitations and caveats: The trial has several limitations:~1. It was open-label.~2. it only enrolled patients on continuous B cell depletion for a minimum of 2 years~3. it took place in a single center.
Plan to share individual participant data: NO
Clinical trial NCT04940949: A Study to Evaluate Lu AF90103 in Healthy Men
Official title: Interventional, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study Part Investigating the Safety, Tolerability, and Pharmacokinetic and -Dynamic Properties of Lu AF90103 and a Double-Blind, Cross-Over Study Part Investigating the Safety Profile After Infusion of Lu AF90103 at Two Rates to Healthy Men
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated based on new safety data.
Enrollment: 15.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-05-26
Primary completion date: 2021-11-23
Completion date: 2021-11-23
Clinical trial NCT02660528: Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder
Official title: Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder: An Open-Label Trial
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study staff change.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-04-30
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Clinical trial NCT03397446: Lisdexamfetamine for Adults With Bulimia Nervosa
Official title: A Feasibility Study to Evaluate Lisdexamfetamine Dimesylate (Vyvanse) in Adults With Bulimia Nervosa
Sponsor: Nova Scotia Health Authority (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Loss of resources due to COVID-19 resulted in insufficient funds to complete the trial as planned. However, sufficient data was collected to fulfill the aims of the trial. Discontinuation is not related to the drug, its use, or adverse events.
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-21
Primary completion date: 2020-05-19
Completion date: 2020-05-19
Plan to share individual participant data: NO
Clinical trial NCT05387707: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
Official title: A Two-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects With Atopic Dermatitis
Acronym: KIND-1
Sponsor: Cara Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: In Part A of the study, oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone.
Enrollment: 287.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-08-16
Primary completion date: 2024-02-02
Completion date: 2024-02-02
Plan to share individual participant data: NO
Clinical trial NCT02674061: Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Official title: A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 376.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-25
Primary completion date: 2019-09-18
Completion date: 2021-03-18
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf